Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2009

Baylor College of Medicine to Use Illumina Infinium® DNA Analysis Products

  • Researchers at Baylor College of Medicine’s Medical Genetics Laboratories will use Illumina’s Infinium® High-Density DNA Analysis products to study genomic imprinting and its role in developmental diseases such as Prader-Willi syndrome, Angelman syndrome, and other disorders caused by uniparental disomy.

    With the Infinium DNA Analysis products, scientists at Baylor will have access to high-resolution scans of entire genomes for chromosomal abnormalities found in genes and disease pathways linked to common developmental diseases and syndromes, according to the company. These products are reported to offer quick and cost-effective screening for single-nucleotide polymorphisms associated with diseases, structural variation, and copy-neutral loss of heterozygosity events such as uniparental disomy.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »